Cargando…

What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity

BACKGROUND: A major handicap in developing a malaria vaccine is the difficulty in pinpointing the immune responses that protect against malaria. The protective efficacy of natural or vaccine-induced immune responses against malaria is normally assessed by relating the level of the responses in an in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinyanjui, Samson M, Bejon, Philip, Osier, Faith H, Bull, Peter C, Marsh, Kevin
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773787/
https://www.ncbi.nlm.nih.gov/pubmed/19860926
http://dx.doi.org/10.1186/1475-2875-8-242
_version_ 1782173900945227776
author Kinyanjui, Samson M
Bejon, Philip
Osier, Faith H
Bull, Peter C
Marsh, Kevin
author_facet Kinyanjui, Samson M
Bejon, Philip
Osier, Faith H
Bull, Peter C
Marsh, Kevin
author_sort Kinyanjui, Samson M
collection PubMed
description BACKGROUND: A major handicap in developing a malaria vaccine is the difficulty in pinpointing the immune responses that protect against malaria. The protective efficacy of natural or vaccine-induced immune responses against malaria is normally assessed by relating the level of the responses in an individual at the beginning of a follow-up period and the individual's experience of malaria infection or disease during the follow-up. This approach has identified a number of important responses against malaria, but their protective efficacies vary considerably between studies. HYPOTHESIS: It is likely that apart from differences in study methodologies, differences in exposure among study subjects within each study and brevity of antibody responses to malaria antigen are important sources of the variation in protective efficacy of anti-malaria immune responses mentioned above. Since malaria immunity is not complete, anyone in an area of stable malaria transmission who does not become asymptomatically or symptomatically infected during follow-up subsequent to treatment is most likely unexposed rather than immune. TESTING THE HYPOTHESIS: It is proposed that individuals involved in a longitudinal study of malaria immunity should be treated for malaria prior to the start of the study and only those who present with at least an asymptomatic infection during the follow-up should be included in the analysis. In addition, it is proposed that more closely repeated serological survey should be carried out during follow-up in order to get a better picture of an individual's serological status. IMPLICATIONS OF THE HYPOTHESIS: Failure to distinguish between individuals who do not get a clinical episode during follow-up because they were unexposed and those who are genuinely immune undermines our ability to assign a protective role to immune responses against malaria. The brevity of antibodies responses makes it difficult to assign the true serological status of an individual at any given time, i.e. those positive at a survey may be negative by the time they encounter the next infection.
format Text
id pubmed-2773787
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27737872009-11-06 What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity Kinyanjui, Samson M Bejon, Philip Osier, Faith H Bull, Peter C Marsh, Kevin Malar J Research BACKGROUND: A major handicap in developing a malaria vaccine is the difficulty in pinpointing the immune responses that protect against malaria. The protective efficacy of natural or vaccine-induced immune responses against malaria is normally assessed by relating the level of the responses in an individual at the beginning of a follow-up period and the individual's experience of malaria infection or disease during the follow-up. This approach has identified a number of important responses against malaria, but their protective efficacies vary considerably between studies. HYPOTHESIS: It is likely that apart from differences in study methodologies, differences in exposure among study subjects within each study and brevity of antibody responses to malaria antigen are important sources of the variation in protective efficacy of anti-malaria immune responses mentioned above. Since malaria immunity is not complete, anyone in an area of stable malaria transmission who does not become asymptomatically or symptomatically infected during follow-up subsequent to treatment is most likely unexposed rather than immune. TESTING THE HYPOTHESIS: It is proposed that individuals involved in a longitudinal study of malaria immunity should be treated for malaria prior to the start of the study and only those who present with at least an asymptomatic infection during the follow-up should be included in the analysis. In addition, it is proposed that more closely repeated serological survey should be carried out during follow-up in order to get a better picture of an individual's serological status. IMPLICATIONS OF THE HYPOTHESIS: Failure to distinguish between individuals who do not get a clinical episode during follow-up because they were unexposed and those who are genuinely immune undermines our ability to assign a protective role to immune responses against malaria. The brevity of antibodies responses makes it difficult to assign the true serological status of an individual at any given time, i.e. those positive at a survey may be negative by the time they encounter the next infection. BioMed Central 2009-10-28 /pmc/articles/PMC2773787/ /pubmed/19860926 http://dx.doi.org/10.1186/1475-2875-8-242 Text en Copyright © 2009 Kinyanjui et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Kinyanjui, Samson M
Bejon, Philip
Osier, Faith H
Bull, Peter C
Marsh, Kevin
What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity
title What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity
title_full What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity
title_fullStr What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity
title_full_unstemmed What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity
title_short What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity
title_sort what you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773787/
https://www.ncbi.nlm.nih.gov/pubmed/19860926
http://dx.doi.org/10.1186/1475-2875-8-242
work_keys_str_mv AT kinyanjuisamsonm whatyouseeisnotwhatyougetimplicationsofthebrevityofantibodyresponsestomalariaantigensandtransmissionheterogeneityinlongitudinalstudiesofmalariaimmunity
AT bejonphilip whatyouseeisnotwhatyougetimplicationsofthebrevityofantibodyresponsestomalariaantigensandtransmissionheterogeneityinlongitudinalstudiesofmalariaimmunity
AT osierfaithh whatyouseeisnotwhatyougetimplicationsofthebrevityofantibodyresponsestomalariaantigensandtransmissionheterogeneityinlongitudinalstudiesofmalariaimmunity
AT bullpeterc whatyouseeisnotwhatyougetimplicationsofthebrevityofantibodyresponsestomalariaantigensandtransmissionheterogeneityinlongitudinalstudiesofmalariaimmunity
AT marshkevin whatyouseeisnotwhatyougetimplicationsofthebrevityofantibodyresponsestomalariaantigensandtransmissionheterogeneityinlongitudinalstudiesofmalariaimmunity